Trending Science
Top 10
FDA approves FAYUVI gene therapy as first treatment for Sanfilippo syndrome type A
The FDA approved Ultragenyx’s FAYUVI gene therapy as the first treatment for Sanfilippo syndrome type A, an ultra-rare inherited neurological disease that can become fatal during adolescence.
OpenAI claims an AI-generated solution to the Navier–Stokes problem
OpenAI says an AI system found a finite-time singularity in the Navier–Stokes equations and released a paper plus Lean formalization, but outside mathematicians are challenging the claim.
Researchers lower a quantum attack estimate for Bitcoin and Ethereum
A reported study cuts the estimated cost of a key quantum-computing step for attacking Bitcoin and Ethereum cryptography by more than half, but broader timing remains uncertain.
In vivo CAR T cells show early promise in neurologic autoimmune disease
An early report describes a single infusion that generated CD19-targeting CAR T cells inside 16 people with difficult neurologic autoimmune disorders, alongside reported clinical improvements.
Our Future Health reports data from 1.9 million participants in a planned five-million-person cohort
Our Future Health has analyzed health and disease patterns from 1.9 million UK participants within a planned five-million-person cohort, offering a large foundation for population-medicine research.
Drug pricing policy is shifting across U.S. markets and payment models
Drug pricing debates are expanding from U.S. negotiations and most-favored-nation deals to subscription models, while affordability, access, and effects on innovation remain unsettled.
Health tech coverage spans startups, digital tools and medical-device investment
Coverage groups together health-tech startups, digital-health initiatives, wearable-company finances, drone delivery and a Pennsylvania ultrasound manufacturing expansion.
Diagnostics are moving from central labs toward point-of-care and consumer testing
Coverage spans faster point-of-care molecular tests, cancer treatment-matching assays, and consumer blood-based reports, alongside laboratory services for infectious disease, genomics, and aging.
Respiratory medicine coverage spans asthma, sleep apnea and pulmonary hypertension
Coverage linked to The Lancet Respiratory Medicine touches asthma response, sleep apnea, cystic fibrosis, postoperative complications and an ECG-based pulmonary hypertension product.
Latest signals
Rare-disease research spans gene therapy, AI diagnosis, and new molecular targets
Coverage points to gene therapy, AI-assisted diagnosis, and molecular studies as active rare-disease areas, while experts debate evidence standards and patients still face diagnostic uncertainty.
The FDA is seeking input on how to regulate generative AI medical devices
The FDA is seeking public feedback on a proposed framework for regulating generative AI-enabled medical devices, including risk classification and competency-based evaluation.
Alfalfa sprouts linked to a multistate E. coli and Salmonella outbreak
U.S. health officials are investigating E. coli and Salmonella infections in 15 states, with alfalfa sprouts identified as the suspected food link.
Trump picks Heidi Overton to lead the FDA
President Donald Trump has picked Dr. Heidi Overton, a White House Domestic Policy Council deputy, to lead the FDA, though the coverage does not establish Senate confirmation.
Lindsay Clancy trial turns on postpartum psychosis and criminal responsibility
The defense has rested in Lindsay Clancy’s triple-murder trial, arguing postpartum psychosis made her legally not responsible for killing her three children.
FDA approves first gene therapy for glycogen storage disease type Ia
The FDA granted accelerated approval to one-time Genglycos for people aged 8 and older with GSDIa, to reduce daily cornstarch intake alongside nutritional management.
Ethiopia’s malaria resurgence is being examined for signs of parasite and testing resistance
Coverage describes a 2024 malaria resurgence in Ethiopia and a study investigating whether parasite mutations, drug resistance, or diagnostic resistance may be weakening disease control.
Pharma’s AI bottleneck may be terminology, not bigger models
Coverage argues that pharmaceutical AI may be constrained less by bigger models than by the terminology and semantic layer used to organize real-world data.
Human brain organoids are reported to model development for five years
Coverage highlights a report that human brain organoids model aspects of development over five years, while leaving methods, scope, and validation details unclear.
Flight attendants and pilots show the highest reported radiation-related cancer mortality
A study of more than 500 occupations found flight attendants and pilots had the highest reported shares of radiation-related cancer deaths, but causation remains unproven.
Signals Gallery
Aryabhatta wrote his most famous treatise, Aryabhatiya, when he was only 23 years old. It contains 121 verses on various topics of mathematics and astronomy, such as the value of pi, the solution of quadratic equations, the calculation of eclipses, and the motion of planets.
Not a painting. A planet losing its temper. This is Jupiter — the heaviest world in the Solar System — shot from so close that NASA’s Juno was skimming the cloud tops, not admiring them from the postcard distance of Earth. What looks like oil on canvas is ammonia, water, and
East Texas A&M researchers propose post-quantum security for Lightning
East Texas A&M researchers report PQLN, a post-quantum security design for Lightning’s communication and routing layers, while noting larger gossip data and no protection for channel funds or on-chain Bitcoin.
East Texas A&M team reports a post-quantum design for Lightning payments
East Texas A&M researchers reportedly released PQLN, a post-quantum cryptography design for Bitcoin’s Lightning Network, but its security and deployment claims remain unverified.
Anthropic system card says METR used an undisclosed source in AI research evaluation
METR reportedly used an undisclosed additional information source to assess Anthropic’s AI research and development capabilities, raising questions about the evaluation’s scope and reproducibility.
Virtual Biotech coordinates AI agents for early drug-development decisions
A Science study introduces Virtual Biotech, a multi-agent AI platform that coordinates specialized agents to analyze biomedical and clinical evidence for early drug-development decisions.
Excited to introduce @ReactorfieldAI Cohort 1: @merge - brain-computer interfaces with no implants, $250M seed led by OpenAI and Bain @episteme - a new R&D institution, cofounded by Louis Andre and Sam Altman @RetroBio_ - unicorn longevity startup, adding 10 healthy years to
Ocugen begins Phase 3 trial of investigational OCU410 gene therapy for geographic atrophy
Ocugen has begun dosing patients in a Phase 3 trial testing investigational gene therapy OCU410 for geographic atrophy linked to dry age-related macular degeneration.
FDA approves FAYUVI gene therapy as first treatment for Sanfilippo syndrome type A
The FDA approved Ultragenyx’s FAYUVI gene therapy as the first treatment for Sanfilippo syndrome type A, an ultra-rare inherited neurological disease that can become fatal during adolescence.
A plant immune receptor is being studied for glycan recognition
A Science article examines whether a plant damage-sensing immune receptor recognizes glycans, but the supplied coverage provides no experimental details.
Samsung Biologics to acquire PolyPeptide Group for $1.8 billion
Samsung Biologics is acquiring Swiss contract manufacturer PolyPeptide Group for $1.8 billion, expanding capacity for peptides, antibodies, and antibody-drug conjugates as demand for obesity treatments grows.
PROFILE trial compares five-year outcomes of two Crohn’s disease treatment strategies
The PROFILE trial reports five-year outcomes comparing top-down therapy with conventional step-up treatment in adults newly diagnosed with Crohn’s disease.
Healthy longevity may depend on linking biology, AI, and clinical innovation
Coverage frames healthy longevity as a cross-disciplinary effort linking biological research, artificial intelligence, and clinical innovation, while leaving specific evidence and interventions unspecified.
FDA places a partial hold on Biohaven’s epilepsy drug trials
The FDA has placed a partial hold on Biohaven’s epilepsy drug, pausing enrollment in pivotal trials and raising questions about the program’s next steps.
Variant-specific B cells may complement SARS-CoV-2 immune memory
Coverage highlights a Science report on variant-specific B cells and imprinted SARS-CoV-2 memory, alongside a Knowable explainer on how the virus evolves.